case_images: PMC5189977_01
case_images: PET/CT (June 18, 2013) showing disease extent after first-line chemotherapy.. Notes: Compared with PET/CT images before first-line chemotherapy, this scan revealed that the nasopharyngeal mass and lymph node metastases were reduced in size, whereas liver and bone metastases had increased in size and number, indicating progressive disease.. Abbreviations: CT, computed tomography; PET, positron emission tomography.
case_images: ott-10-067Fig1.jpg
case_images: PMC5189977_01_ott-10-067Fig1.jpg
case_images: f1-ott-10-067
case_images: The second PET/CT scan (June 18, 2013) revealed that the nasopharyngeal mass and lymph node metastases were reduced in size, whereas liver and bone metastases had increased in size and number (Figure 1), indicating progressive disease.
case_images: PET/CT (September 2, 2013) displaying relatively favorable tumor burden with bevacizumab combined with the agents already being administered.. Notes: Although bone metastases remained stable, other metastatic sites including liver metastases were reduced in size and number after addition of bevacizumab to chemotherapy.. Abbreviations: CT, computed tomography; PET, positron emission tomography.
case_images: ott-10-067Fig2.jpg
case_images: PMC5189977_01_ott-10-067Fig2.jpg
case_images: f2-ott-10-067
case_images: The third PET/CT scan (September 2, 2013) demonstrated stable bone metastases and disease reduction in other metastatic sites, suggesting stable disease (SD) (Figure 2).
case_images: PET/CT (February 8, 2014) showing significantly progressive disease after changed regimen and discontinuation of treatment because of liver dysfunction.. Notes: Liver, bone, and lymph node metastases were increased in size and number.. Abbreviations: CT, computed tomography; PET, positron emission tomography.
case_images: ott-10-067Fig3.jpg
case_images: PMC5189977_01_ott-10-067Fig3.jpg
case_images: f3-ott-10-067
case_images: The PET/CT was applied again for assessing the response to the above regimen in February 8, 2014 (Figure 3).